Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1001883 | 0.99 | F10 (0.48) | F10KDM4ELMNAF2ABCB11 | |
| SCHEMBL3098386 | 0.81 | HPGD (0.46) | F10KDM4ELMNAHPGDTSHR | |
| SCHEMBL8228494 | 0.80 | F10 (0.45) | F10KDM4ELMNAF2ABCB11 | |
| Hydrochloric Acid SCHEMBL1002393 | 0.79 | F10 (0.45) | F10KDM4ELMNAF2ABCB11 | |
| SCHEMBL8229199 | 0.79 | F10 (0.49) | F10KDM4ELMNAF2ABCB11 | |
| SCHEMBL1159493 | 0.79 | HPGD (0.43) | F10KDM4ELMNAHPGDTSHR | |
| SCHEMBL1106573 | 0.79 | HPGD (0.43) | F10KDM4ELMNAHPGDTSHR | |
| SCHEMBL1098920 | 0.79 | HPGD (0.42) | F10KDM4ELMNAF2HPGD | |
| SCHEMBL1097324 | 0.79 | HPGD (0.42) | F10KDM4ELMNAHPGDTSHR | |
| Hydrochloric Acid SCHEMBL1001890 | 0.78 | F10 (0.49) | F10KDM4ELMNAF2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| WO-2007137792-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | F2, VKORC1, HMBS | F10 104/4885KDM4E 2434/4885LMNA 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.